The Journal of clinical psychiatry···
Duloxetine compared to placebo for treating long-term mild depression
Updated
Abstract
After 10 weeks, 65.5% of duloxetine-treated subjects responded compared to 25.0% of those on placebo.
- Duloxetine treatment resulted in significantly lower scores on the 24-item Hamilton Depression Rating Scale compared to placebo.
- The response rate for duloxetine was 65.5%, while the remitter rate was 55.2%, both significantly higher than placebo rates.
- No significant differences were observed between duloxetine and placebo in social functioning or overall global assessment of functioning.
- Findings indicate that duloxetine may be effective for treating chronic nonmajor depressive disorder.
Simplified
OBJECTIVE: Numerous double-blind studies have assessed the efficacy of antidepressants in treating chronic depressive disorder, including dysthymic disorder, low-grade chronic depression. However, there are no double-blind, placebo-controlled studies of serotonin-norepinephrine reuptake inhibitors in chronic depressive disorder.
METHOD: Outpatients with chronic depressive disorder, but without concurrent major depressive disorder (MDD), were randomly assigned to prospective double-blind duloxetine (beginning at 30 mg/d, increased to a maximum dose of 120 mg/d) versus placebo for 10 weeks. Inclusion criteria were current DSM-IV-TR diagnosis of dysthymic disorder or depression not otherwise specified, age 18-75 years, and a Hamilton Depression Rating Scale (HDRS) score ≥ 12. Exclusion criteria included current major depression. The study was conducted between August 2006 and December 2011. HDRS, Cornell Dysthymia Rating Scale (CDRS), Clinical Global Impressions (CGI), Beck Depression Inventory (BDI), Global Assessment of Functioning (GAF), Social Adjustment Scale (SAS), and other assessments were administered at each visit. We hypothesized that duloxetine would be superior to placebo in (1) 24-item HDRS total score, (2) the percentage of subjects classified as responders and remitters, and (3) secondary measures (CDRS, BDI, CGI). Response was defined as > 50% decrease in 24-item HDRS and CGI-Improvement scale score of 1 or 2 ("very much improved" or "much improved"). Remission was defined as HDRS-17 item score ≤ 4 and 0 on item 1 of the HDRS (depressed mood).
RESULTS: 65 subjects were enrolled, of whom 57 began medication. They ranged in age from 19 to 70 years (mean ± SD = 41.63 ± 11.22) and included 24 women and 33 men. Baseline 24-item HDRS score (mean ± SD) for both groups was 20.75 ± 4.92. After 10 weeks, duloxetine-treated subjects had significantly lower 24-item HDRS scores than placebo-treated subjects (time-by-drug group effect on analysis of variance: F1,55 = 9.43, P = .003). Responder and remitter analyses significantly favored duloxetine treatment. The response rate was 65.5% for duloxetine versus 25.0% for placebo (χ(2)(1) = 9.43, P = .003); and the remitter rate was 55.2% for duloxetine versus 14.3% for placebo (χ(2)(1) = 10.46, P = .002). After 10 weeks, duloxetine-treated subjects did not differ significantly better from placebo-treated subjects on the SAS (time-by-drug group effect on analysis of variance: F(1,46) = 0.35, P = .555) or on the GAF (time-by-drug group effect on analysis of variance: F(1,51) = .01, P = .922).
CONCLUSIONS: Results on the 24-item HDRS, CGI, and CDRS suggest that duloxetine is efficacious in acute treatment of chronic nonmajor depressive disorder. Response and remission rates also differed significantly, favoring duloxetine treatment, but BDI, GAF, and social functioning (Social Adjustment Scale) did not. Duloxetine appears to be effective in acute treatment of nonmajor chronic depression.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00360724.
Related papers
Aug '09
Desvenlafaxine 50 and 100 mg/day for treating major depression: an 8-week controlled trial and combined analysis of three studies
cited by 51 papers
randomized controlled trial
Sep '10
Effectiveness and safety of daily 60 mg and 120 mg duloxetine in patients hospitalized for severe depression
top 10% journal
cited by 12 papers
randomized controlled trial
Aug '11
Escitalopram compared to placebo for treating persistent mild depression
top 30% journal
cited by 10 papers
randomized controlled trial
Dec '04
Duloxetine compared to placebo and paroxetine for short- and long-term treatment of major depression
cited by 213 papers
randomized controlled trial
Oct '04
Duloxetine compared to placebo for treating fibromyalgia with and without major depression in a double-blind, multicenter trial
cited by 476 papers
randomized controlled trial
Aug '12
An 8-week study testing different doses of Lu AA21004 for effectiveness and side effects in adults with major depression
top 10% journal
cited by 121 papers
randomized controlled trial
Aug '11
Duloxetine’s effects compared to placebo in depression patients with painful symptoms
cited by 27 papers
randomized controlled trial
Aug '11
Duloxetine compared to placebo for treating major depression and related physical pain: a repeat study
top 30% journal
cited by 24 papers
randomized controlled trial
Jul '06
Safety and side effects of increasing doses of duloxetine for major depression
cited by 30 papers
controlled clinical trial
Jan '05
Duloxetine's effectiveness for major depression with and without melancholic symptoms
top 10% journal
cited by 50 papers
meta-analysis